Table 1 Clinicalpathological characteristics of the investigated HCC patients

From: TRIM50 suppressed hepatocarcinoma progression through directly targeting SNAIL for ubiquitous degradation

  Cohort 1 (n = 79) Cohort 2 (n = 51) Cohort 3 (n = 52)
  (for IHC) (for qRT-PCR) (for western blot)
Gender
  Male 68 (86.1%) 40 (78.4%) 42 (80.8%)
  Female 11 (13.9%) 11 (21.6%) 10 (19.2%)
Age
  <54 32 (40.5%) 19 (32.3%) 21 (40.4%)
  ≥54 47 (59.5%) 32 (62.7%) 31 (59.6%)
Tumor size
  <5 cm 48 (60.7%) 28 (54.9%) 16 (30.8 %)
  ≥5 cm 31 (39.3%) 23 (45.1%) 36 (69.2%)
Liver cirrhosis history
  Yes 65 (82.3%) 34 (66.7%) 32 (62.7%)
  No 14 (17.7%) 17 (33.3%) 20 (39.3%)
TNM stages
  I 38 (48.1%) 22 (43.1%) 23 (44.2%)
  II 2 (2.5%) 5 (9.8%) 3 (5.8%)
  III 32 (40.5%) 14 (27.5%) 16 (30.8%)
  IV 5 (6.3%) 7 (13.7%) 5 (9.6%)
  Not available 2 (2.5%) 3 (5.9%) 5 (9.6%)
Regional lymph nodes
  N0 73 (92.4%) 44 (86.3%) 44 (84.6%)
  N1 6 (7.6%) 7 (13.7%) 8 (15.4%)
BCLC stages
  0 6 (7.6%) 1 (2.0%) 11 (21.2%)
  A 30 (38.0%) 10 (19.6%) 18 (34.6%)
  B 10 (12.6%) 4 (7.8%) 8 (15.4%)
  C 24 (30.4%) 15 (29.4%) 10 (19.2%)
  D 2 (2.5%) 0 0
  Not available 7 (8.9%) 21 (41.2%) 5 (9.6%)
Distant metastasis
  No 13 (16.5%) 46 (90.2%) 33 (63.5%) 
  Yes 12 (15.4%) 3 (5.9%) 11 (21.2%)
  Not available 54 (68.1%) 2 (3.9%) 8 (15.3%)